A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 39600 participants.

Also called NCT04505098

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 39,600 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04505098
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04505098. Randomized; single masking; primary purpose prevention. Start 2020-08-07 (actual); primary completion 2022-12-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
Acronym
MITIGATE
Condition
Covid19
Condition
Atherosclerosis
Condition
Cardiovascular Diseases
Condition
Upper Respiratory Tract Infections
Intervention (Drug)
Icosapent ethyl
Lead sponsor
Kaiser Permanente (class: other)
Collaborator
Amarin Corporation (class: not stated)

Record details

Record id
cardio:ct-nct04505098
Content hash
22d1c9746bd1f1c781aadbd5ae3fd6c10b49952e6129a3724f9f999c1e40097c